NASDAQ · Health care

Barinthus Biotherapeutics plc. (BRNS)

It posted a net loss of $41.8M. In fiscal 2025 capital spending exceeded operating cash flow by $48M. At June 30, 2026 it held $59.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.

Price

$0.74

-2.49% on the day · September 8, 2026

52-week range $0.51 to $1.83

Market cap

$30.2M

What Barinthus Biotherapeutics plc. does

Barinthus Biotherapeutics plc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BRNS.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$0	-$70.6M	-$66.4M	-$1.64	-$48M
2024	$15M	-$68M	-$61.1M	-$1.55	-$29.8M
2023	$802K	-$83.9M	-$73.3M	-$1.91	-$56.3M
2022	$44.7M	-$4M	$5.3M	$0.14	-$20.6M
2021	$268K	-$45.2M	-$50.9M	-$1.96	-$33.7M
2021	$4.8M	-$20M	-$17.7M	-$2.24	-$11.3M

Full financial statements: income, balance sheet and cash flow

Next report expected around November 6, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 7, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What Barinthus Biotherapeutics plc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 21, 2026
Deregistration 15-12G
September 11, 2026
Passive stake changed SCHEDULE 13G/A
September 9, 2026
Form 25 filing 25
September 9, 2026
Form S-8 POS filing S-8 POS
September 9, 2026
Form S-8 POS filing S-8 POS
September 9, 2026
Form S-8 POS filing S-8 POS
September 9, 2026
Form S-8 POS filing S-8 POS
September 9, 2026
Form S-8 POS filing S-8 POS
September 9, 2026
Form POS AM filing POS AM
September 9, 2026
Change in control 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 11, 2026. Insider transactions on SEC

Insider trades

What the people running Barinthus Biotherapeutics plc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 11 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

Bought (open market)

last 90 days

Sold

last 90 days

Date	Insider	What	Shares	Price	Value	Filing
September 9, 2026	Oxford Science Enterprises plcformer 10% owner	Other change	8,797,770	$0.11	$976.6K	Form 4
September 9, 2026	Dawes Karen ADirector	Other change	1,700	-	-	Form 4
September 9, 2026	Enright WilliamChief Executive Officer, Director	Other changeindirect	728,454	-	-	Form 4
September 9, 2026	Enright WilliamChief Executive Officer, Director	Other changeindirect	514,923	-	-	Form 4
September 9, 2026	Hammacher AlexDirector	Other change	3,000	-	-	Form 4
September 9, 2026	Hooftman LeonChief Medical Officer	Received as pay	361,530	-	-	Form 4
September 9, 2026	Hooftman LeonChief Medical Officer	Other change	361,530	-	-	Form 4
September 9, 2026	Morgon Pierre A.Director	Other change	10,506	-	-	Form 4
September 9, 2026	Phillips Anne M.Director	Other change	3,000	-	-	Form 4
September 9, 2026	Scheeren JosephDirector	Other change	23,000	-	-	Form 4
September 9, 2026	Wright RobinDirector	Other change	48,256	-	-	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns BRNS

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
M&G Plc on behalf of certain subsidiaries No13G, passive	13.19%	5,197,349	November 1, 2024
Frank W. Cawood13G, passive	8.4%	3,384,513	February 11, 2025
International Generosity Foundation Trust13D, may seek influence	6.7%	2,734,189	April 13, 2026

Latest filings below 5%: Oxford Science Enterprises plc 0% (September 11, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about BRNS

What does Barinthus Biotherapeutics plc. do?

Barinthus Biotherapeutics plc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BRNS.

Is Barinthus Biotherapeutics plc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $41.8M.

When did Barinthus Biotherapeutics plc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the deregistration from September 21, 2026.

Similar companies

Compare BRNS with

Compare BRNS with any company

Follow BRNS

Get an email when Barinthus Biotherapeutics plc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow BRNS: get an email when it files

Where the numbers come from

Financial figures are the values Barinthus Biotherapeutics plc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.